AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29176494
Drug: Higher PERT
RxNorm normalized name: Pert Plus Dandruff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher PERT dosing strategy
Trial: 29177070
Drug: MIS416 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MIS416 treatment for 12 weeks
Trial: 29177070
Drug: MIS416 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MIS416 treatment
Trial: 29177094
Drug: MAGE-A3 immunotherapeutic
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-A3 immunotherapeutic combined with dacarbazine (up to 24 doses of MAGE-A3 immunotherapeutic and eight doses of dacarbazine)
Trial: 29177471
Drug: Baseline subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline subcutaneous adipocyte volume
Trial: 29177699
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 at 25 mg
Trial: 29177699
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 at 50 mg
Trial: 29177699
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 at 100 mg
Trial: 29178102
Drug: Fluorouracil-based chemotherapy
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil-based chemotherapy
Trial: 29179674
Drug: suPAR levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suPAR levels ≥3.00 ng/ml
Trial: 29179751
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy (45-50.4 GyE in 1.8 GyE fractions 5-6 times per week)
Trial: 29180545
Drug: Clinical pharmacist-led
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist-led medication therapy management (MTM) service enhanced by a clinical decision support system (CDSS) and pharmacogenomics (PGx) testing.
Trial: 29180633
Drug: Adaptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive therapy using patient-specific tumor dynamics
Trial: 29180633
Drug: Standard abiraterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard abiraterone dosing
Trial: 29182496
Drug: BGJ398 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGJ398 125 mg once daily for 21 days, then 7 days off (28-day cycles)
Trial: 29182729
Drug: Opioids (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids (morphine equivalent dose given 24 hours prior to extubation)
Trial: 29183928
Drug: Normothermic machine
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normothermic machine perfusion of the liver (NMP-L) following a period of static cold storage.
Trial: 29184781
Drug: Radiation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation with coordinated combined chemotherapy
Trial: 29185557
Drug: Low-dose IV
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IV alteplase (0.6 mg/kg)
Trial: 29185557
Drug: Standard-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose IV alteplase (0.9 mg/kg)
Trial: 29185786
Drug: Low exposure
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low exposure desvenlafaxine (20, 30, or 35 mg/day based on baseline weight)
Trial: 29185786
Drug: High exposure
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High exposure desvenlafaxine (25, 35, or 50 mg/day based on baseline weight)
Trial: 29188387
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg q.d.
Trial: 29188408
Drug: Demcizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demcizumab (5 mg/kg)
Trial: 29188408
Drug: Demcizumab (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demcizumab (2.5, 5.0, and 7.5 mg/kg)
Trial: 29188408
Drug: Demcizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demcizumab (5 mg/kg q3-weekly ×4)
Trial: 29188469
Drug: Merestinib (type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merestinib (type II MET kinase inhibitor)
Trial: 29188469
Drug: Emibetuzumab (bivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emibetuzumab (bivalent anti-MET antibody)
Trial: 29188469
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Merestinib and Emibetuzumab
Trial: 29189665
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) of busulfan
Trial: 29189665
Drug: Initial busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial busulfan dose based on age/weight
Trial: 29189950
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care program using a foam stick (Period 1)
Trial: 29189950
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care program using a foam stick and tooth brushing with aspiration (Period 2)
Trial: 29189950
Drug: Cost assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost assessment of the oral care program
Trial: 29191334
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for secondary mitral regurgitation
Trial: 29191916
Drug: Duvelisib 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duvelisib 8 to 100 mg twice daily (MTD determined as 75 mg twice daily)
Trial: 29191916
Drug: Duvelisib 25
RxNorm normalized name: duvelisib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duvelisib 25 or 75 mg twice daily continuously
Trial: 29193547
Drug: telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telbivudine 600 mg/day from gestation 28-32 weeks to 3-4 weeks postpartum
Trial: 29193547
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antiviral agent)
Trial: 29194623
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation plus perioperative SOX chemotherapy
Trial: 29196412
Drug: Vadastuximab talirine
RxNorm normalized name: Vadastuximab talirine
DrugBank: Vadastuximab talirine (DB11884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadastuximab talirine IV at 40 µg/kg
Trial: 29196412
Drug: Vadastuximab talirine
RxNorm normalized name: Vadastuximab talirine
DrugBank: Vadastuximab talirine (DB11884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadastuximab talirine IV at 5-60 µg/kg or 20 µg/kg on days 1 and 4 of 21-day cycles
Trial: 29197547
Drug: 270 μg
RxNorm normalized name: G 207
DrugBank: G207 (DB05827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 μg of aerosolized albuterol sulfate administered with a metered dose inhaler with space chamber
Trial: 29198079
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin and naproxen sodium
Trial: 29198079
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (low-dose aspirin only)
Trial: 29198845
Drug: Gardening frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardening frequency (monthly or weekly)
Trial: 29199321
Drug: ACC-001 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC-001 3 µg + QS-21
Trial: 29199321
Drug: ACC-001 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC-001 10 µg + QS-21
Trial: 29201402
Drug: Correct implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correct implant knowledge
Trial: 29201402
Drug: Intent to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intent to use implant
Trial: 29202623
Drug: ANX005, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANX005, administered intravenously once weekly for 4 weeks
Trial: 29202623
Drug: First-in-human starting
RxNorm normalized name: HUMAN FIRST MILK
DrugBank: Human colostrum (DB19286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-in-human starting dose of ANX005
Trial: 29203493
Drug: Trough concentrations
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trough concentrations of >15 mg/liter
Trial: 29203493
Drug: AUC-guided dosing
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUC-guided dosing with BestDose Bayesian software
Trial: 29203585
Drug: selinexor (3-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selinexor (3-60 mg/m2)
Trial: 29203590
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human IL15 (rhIL15)
Trial: 29204958
Drug: Ingenol disoxate
RxNorm normalized name: Ingenol disoxate
DrugBank: Ingenol disoxate (DB15109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingenol disoxate gel
Trial: 29206944
Drug: Kisspeptin-54 (9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kisspeptin-54 (9.6 nmol/kg, one injection)
Trial: 29206944
Drug: Kisspeptin-54 (9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kisspeptin-54 (9.6 nmol/kg, two injections at 10 h interval)
Trial: 29207608
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan (BU) dose adjustment following therapeutic drug monitoring
Trial: 29207608
Drug: Genotype-guided BU
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided BU dose adjustments
Trial: 29208007
Drug: One session
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One session of physical therapy
Trial: 29209104
Drug: IL-6R antagonist
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-6R antagonist therapy
Trial: 29209458
Drug: Pre-meal almond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-meal almond group (PM) - 56 g of almonds consumed before meals
Trial: 29209458
Drug: Snack almond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snack almond group (SN) - 56 g of almonds consumed as a snack between meals
Trial: 29209525
Drug: Crizotinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (250 mg twice daily; 3 week continuous treatment cycles)
Trial: 29209946
Drug: Sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 150 mg every 2 weeks via pen
Trial: 29209946
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg every 2 weeks via pen
Trial: 29209946
Drug: Sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 150 mg every 2 weeks via syringe
Trial: 29209946
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg every 2 weeks via syringe
Trial: 29210056
Drug: Blood-based precision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-based precision medicine test (ASGES)
Trial: 29210351
Drug: Malaria treatment
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malaria treatment during pregnancy, specific intervention details not provided.
Trial: 29210443
Drug: ACC-001 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC-001 3 µg + QS-21 adjuvant (50 µg)
Trial: 29210443
Drug: ACC-001 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC-001 10 µg + QS-21 adjuvant (50 µg)
Trial: 29210791
Drug: Closed-loop control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop control of propofol and remifentanil infusions using WAVCNS feedback in phase I
Trial: 29210791
Drug: Closed-loop control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop control of propofol and remifentanil infusions using WAVCNS feedback in phase II
Trial: 29211618
Drug: Regimen DD4A
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen DD4A (vincristine, dactinomycin, and doxorubicin) and radiation therapy
Trial: 29211678
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy with AAV vector (5×10 dose)
Trial: 29211678
Drug: Before vector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before vector administration
Trial: 29211678
Drug: After vector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After vector administration
Trial: 29211870
Drug: Denosumab (fixed-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (fixed-dose, cumulative dose 47 to 98 mg/kg for 1.3 to 4 years)
Trial: 29211870
Drug: Denosumab (fixed-dose)
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab (fixed-dose)
Trial: 29212544
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg rosuvastatin daily
Trial: 29212734
Drug: Neoadjuvant GTX
RxNorm normalized name: toremifene
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant GTX (gemcitabine 750 mg/m², docetaxel, capecitabine)
Trial: 29213243
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM) efficacy on CHF patients
Trial: 29213269
Drug: ME-TRAP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME-TRAP and EPI vaccines
Trial: 29213281
Drug: Iron isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron isomaltoside (mean dose 1100 mg, with some patients receiving above 1000 mg)
Trial: 29214034
Drug: Abatacept (~10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (~10 mg/kg/month)
Trial: 29216353
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy in transwomen
Trial: 29216353
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy in transmen
Trial: 29216400
Drug: Crizotinib 250
RxNorm normalized name: crizotinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib 250 mg bd
Trial: 29217288
Drug: Avelumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab (10 mg/kg, 1 h intravenous infusion) every 2 weeks until confirmed disease progression, unacceptable toxicity, or other criterion for withdrawal.
Trial: 29217776
Drug: Melphalan 200
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 200 mg/m
Trial: 29566106
Drug: Avelumab treatment
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab treatment
Trial: 29220505
Drug: ab+/ins- (antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ab+/ins- (antibody positive/insulin negative)
Trial: 29220505
Drug: ab+/ins+ (antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ab+/ins+ (antibody positive/insulin positive)
Trial: 29220505
Drug: ab-/ins- (antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ab-/ins- (antibody negative/insulin negative)
Trial: 29222199
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin at initial doses of 1.8 or 2.4 mg/kg every 3 weeks
Trial: 29222649
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (two 220 mg capsules of zinc sulfate per day for 3 months)
Trial: 29223443
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg/d) for 18 months
Trial: 29223912
Drug: Maternal buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal buprenorphine dose at delivery
Trial: 29224506
Drug: High-dose AAV5-hFVIII-SQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose AAV5-hFVIII-SQ
Trial: 29225903
Drug: Prasugrel or
RxNorm normalized name: prasugrel Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel or ticagrelor as loading P2Y inhibitor
Trial: 29225903
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with optional glycoprotein IIb/IIIa inhibitor treatment
Trial: 29226268
Drug: Latanoprost (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost (one drop daily at bedtime for seven days)
Trial: 29226797
Drug: Axicabtagene ciloleucel
RxNorm normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axicabtagene ciloleucel (axi-cel) CAR T-cell therapy
Trial: 29229365
Drug: Contralateral control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contralateral control area of spongy alveolar bone without treatment
Trial: 29229594
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV) and nivolumab (Nivo) combination treatment
Trial: 29230323
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA treatment
Trial: 29230539
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) at a dose of 0.4 mg/kg
Trial: 29233163
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of autologous bone marrow mesenchymal stem cells (BM-MSCs)
Trial: 29233751
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with intravenous immunoglobulin
Trial: 29233792
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) supplementation (2 × 600mg, twice daily, for 30 days)
Trial: 29234503
Drug: Enteral cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral cholecalciferol loading dose (10,000 IU/kg, maximum of 400,000 IU)
Trial: 29234955
Drug: End of
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End of treatment measures of mental health status, work ability, generalized self-efficacy, and expectations of future work ability.
Trial: 29234955
Drug: Expectancy of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectancy of future work ability improvement or positivity from before to the end of treatment.
Trial: 29235365
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination therapy with 20 mg azilsartan, 5 mg amlodipine, and 12.5 mg hydrochlorothiazide (AZL/AML/HCTZ)
Trial: 29235365
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination therapy with AZL/AML/HCTZ
Trial: 29235365
Drug: AZL/AML therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL/AML therapy
Trial: 29238851
Drug: Mocetinostat 90
RxNorm normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mocetinostat 90 mg TIW + gemcitabine 1000 mg/m²
Trial: 29239002
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg osimertinib once daily
Trial: 29239953
Drug: TXA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA (1 g intravenously)
Trial: 29240542
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal